Endoscopic Treatment in Chronic Pancreatitis

Yue Sun Cheung and Paul Bo-San Lai
Division of Hepato-biliary and Pancreatic Surgery, Department of Surgery,
The Chinese University of Hong Kong, Honk Kong,
China

1. Introduction

Chronic pancreatitis can give rise to relapsing episodic or persistent upper abdominal pain (Frulloni et al., 2010). Apart from the derangement of endocrine and exocrine functions, it can cause local complications such as pancreatic ductal stenosis, formation of intraductal stones and development of pseudocysts (Strobel et al., 2009). Management of these complications can be challenging in some patients. Various surgical drainage and resection procedures had been described with successful results (Strobel et al., 2009) but they were technically demanding and carried significant morbidities (Schnelldorfer et al., 2007). With the advancement in endoscopic treatments and novel techniques, some of the conventional open procedures have been replaced by endoscopic or minimally invasive techniques. In this chapter, we reviewed various endoscopic procedures available in treating patients with chronic pancreatitis, namely endoscopic sphincterotomy, stricture dilatation, stenting, stone extraction, endoscopic ultrasound-guided pseudocyst drainage and celiac plexus block. The indications, techniques and efficacy of endoscopic treatments were discussed in this chapter.

2. Indications of endoscopic treatment

Endoscopic treatment can be applied to different pathologic processes associated with chronic pancreatitis. These processes include pancreatic ductal strictures, stones and pancreatic pseudocyst formation (Sherman & Lehman, 1998). These processes can lead to ductal obstruction and parenchymal hypertension, resulting in upper abdominal pain (Strobel et al., 2009). Restoration of the drainage of the main pancreatic duct by a combination of sphincterotomy, stricture dilatation, stone extraction and stent placement are indicated in symptomatic patients with these pathologies (Strobel et al., 2009).

Apart from pain, chronic pancreatitis might also cause pseudocyst formation, leading to abscess, ascites and pleural effusion secondary to rupture and occasionally pseudoaneurysm formation. The formation of pseudoaneurysm could in turn lead to massive gastrointestinal tract bleeding or interperitoneal haemorrhage (Lai et al., 1997). Therefore, drainage of pseudocyst is another common indication for endoscopic treatment.

Recently, pancreatic neuritis secondary to inflammatory infiltration and hypertrophy of pancreatic nerves was proposed as the alternative mechanism causing abdominal pain in chronic pancreatitis (Strobel et al., 2009). Endoscopic ultrasound-guided celiac plexus block
had been employed safely for pain relief in chronic pancreatitis with minimal complication (Avula & Sherman, 2010; Puli SR et al., 2009).

Fig. 1. Multiple pancreatic ductal stones with ductal dilatation on ERCP.

Although indications of endoscopic therapy to chronic pancreatitis might extend with more data coming up, it has little role in asymptomatic main pancreatic duct dilatation at the moment. There has been no data to suggest the restoration of the pancreatic outflow can delay the process of pancreatic parenchymal atrophy or improve the endocrine and exocrine function of pancreas (Frulloni et al., 2010).

3. Techniques of endoscopic treatment

With the advance in technology and improvement in endoscopic skills, various endoscopic therapies in chronic pancreatitis are made possible. The following sections described the common techniques used in chronic pancreatitis.

3.1 Endoscopic sphincterotomy

Endoscopic sphincterotomy can be performed by either standard pull-type sphincterotomy after wire-guided cannulation or pre-cut on pancreatic stent (Buscaglia & Kalloo, 2007). However, unlike biliary sphincterotomy, the direction of pancreatic sphincterotomy should be directed towards the 1 to 2 o’clock position of the papillary orifice. An incision of 5 to 10mm in length is usually made with the pure cutting current, so that damage to the pancreas and
subsequent stenosis of papilla can be avoided. A pancreatic stent is usually put in temporarily to prevent ductal obstruction by post-sphincterotomy edema (Buscaglia & Kalloo, 2007).

Occasionally pathology at the minor papilla such as pancreatic divisum, can be a cause of chronic pancreatitis (Tarnasky et al., 1997). Minor papillotomy, dividing only the mucosal mound rather than true sphincterotomy, can be performed to achieve decompression of the dorsal duct (Buscaglia & Kalloo, 2007). A soft tip 0.035 inch hydrophilic guidewire is generally used for wire-guided cannulation. After deep cannulation achieved, standard pull-type sphincterotomy can be performed, directing along the course of the dorsal duct, usually at 11 o’clock position (Buscaglia & Kalloo, 2007).

Endoscopic sphincterotomy can also be performed as the primary treatment for conditions leading to chronic pancreatitis, e.g. sphincter of Oddi dysfunction. It is, however, more commonly used to gain access to the pancreatic duct and facilitate further endoscopic treatment as described in later section.

### 3.2 Pancreatic ductal dilatation and stenting

Patients with focal main pancreatic duct stricture at the head or body can be managed by dilatation and stenting, usually after pancreatic sphincterotomy. A guidewire can be passed proximal to the stricture site, over which graduated dilating catheter or hydrostatic balloon dilator can be used for stricture dilatation. Since these strictures from chronic pancreatitis are very fibrotic, simple dilatation alone usually does not give long term response (Yoo & Lehman, 2009). Endoscopic stents are therefore placed across the strictures to adequately expand the lumen to achieve a good flow of pancreatic juice even after the stent is removed. Different sizes of stents are used for different purpose, but they should not be larger than the diameter of the distal duct. In general, stents for pancreatitis prophylaxis are usually 3-5 Fr in size, whereas single or multiple stents up to 7 to 10 Fr might be necessary after stricture dilatation (Yoo & Lehman, 2009). The optimal duration to leave a stent in-situ is not known
Chronic Pancreatitis (Sherman & Lehman, 1998). It can be left till symptoms reappears or can be exchanged at 3-monthly interval (Yoo & Lehman, 2009). In patients with dominant pancreatic duct strictures, the technical success rate up to 91% had been reported but only 62% of these patients had symptoms improved. The morbidity and mortality rate reported were 18% and 1% respectively (Yoo & Lehman, 2009).

3.3 Extraction of pancreatic ductal stones

Removal of pancreatic ductal stones usually requires a pancreatic sphincterotomy to facilitate access to the duct. In cases where strictures distal to the stones are present, dilatation with catheters or hydrostatic balloons is also required. Balloons and baskets are common accessories for stone retrieval and in difficult cases, such as bending across a tortuous duct, over-the-wire accessories might be necessary (Sherman & Lehman, 1998). For very big and hard stones, lithotripsy either using laser or electrohydrolitic lithotripsy (EHL) or extra-corporeal shock wave lithotripsy (ESWL) would frequently be necessary.

![Fig. 3. Pancreatic duct stone removed with basket.](image)

For laser or electrohydrolitic lithotripsy, a small caliber through-the-scope pancreatoscope is needed to guide the lithotripsy under direct vision. The pancreatoscope can be passed down the duodenoscope over guidewire to gain access to the pancreatic duct (Howell et al., 1999). After visualization of the stone, the EHL probe or laser fibre is passed down the channel of the pancreatoscope (Howell et al., 1999; Hirai et al., 2004). In case of EHL, lithotripsy is performed with saline lavage to optimize energy penetration. Stone fragments can then be removed by basket or lavage over balloon catheter. A stent without forward flap is usually placed temporarily at the end of procedure to facilitate drainage (Howell et al., 1999).
3.4 Combined endoscopy and extracorporeal shockwave lithotripsy

Extracorporeal shock wave lithotripsy (ESWL) is another adjunct in the endoscopic treatment of pancreatic duct stones (Lawrence et al., 2010). It can fragment the stones and reduce stone burden, thus facilitating endoscopic clearance of the pancreatic duct. Endoscopic sphincterotomy is usually performed before ESWL. Pancreatic duct stones can be localized either by fluoroscopy or ultrasonography during lithotripsy. Contrast instillation through a nasopancreatic drain could sometimes help with the localization of radiolucent stone (Choi & Kim, 2006). Occasionally the nasopancreatic drain can also be used for saline irrigation (Costamagna et al., 1997) and obtain follow-up pancreatograms after ESWL. If pancreatic ductal strictures are present, dilatation and stenting might be performed to facilitate ductal clearance and decompression after stones fragmentation (Choi & Kim, 2006).

3.5 Drainage of pancreatic pseudocyst

Endoscopic drainage of pseudocyst involved the creation of communication between the pseudocyst and gastrointestinal lumen, so that the cyst content can be drained internally (Sherman & Lehman, 1998). The access to the pseudocyst can be guided by means of endoscopic ultrasound (EUS). This facilitate transmural needle placement even when no bulge can be seen through the endoscope and avoid puncturing the vessels on gastroduodenal wall.

Fig. 4. Pancreatoscope passed down through standard duodenoscope to visualize the pancreatic duct lumen.
Fig. 5. Computed tomography showing pseudocyst near the tail of pancreas with mild pancreatic duct dilatation and stones proximal to the cyst.

Fig. 6. Endoscopic view of plastic stent and double pigtail catheters inserted under endoscopic ultrasound guidance to form a cystogastrostomy.
The pseudocyst is punctured under the guidance of a linear echoendoscope. A guidewire is passed into the cyst under fluoroscopic control to form at least 2 loops. The cystogastrostomy or cystoduodenostomy is then dilated with balloon catheter to 6-8mm size, follow which a double pigtail stent will be inserted over the wire to establish the drainage. Second or multiple stents will then be inserted under endoscopic and fluoroscopic guidance by recannulation of the pseudocysts (Seewald et al., 2009). In case of abscess or debris are present inside the pseudocyst, saline irrigation and aspiration of the cyst content can be achieved through a nasocystic catheter instead of internal stent.

As recannulation of the pseudocyst can sometimes be cumbersome, some endoscopists advocated the use of “double-wire” technique, in which 2 wires were inserted into the pseudocyst through a double lumen catheter after the pseudocyst is punctured. Simultaneous stents or nasocystic catheters insertion can then be performed under fluoroscopic guidance over the 2 wires in place. (Itoi et al., 2009).

Complications of EUS-guided drainage include bleeding, perforation and infection. Coagulopathy has to be corrected and prophylactic antibiotics should be given before the procedure. Only pseudocyst with mature wall and within 1cm from gastrointestinal lumen should be considered for endoscopic drainage (Seewald et al., 2009).

Although EUS-guided drainage is a promising technique for decompression of pseudocyst in chronic pancreatitis, case selection is very important for success. Technical success rate, defined as the feasibility of access and drain insertion to the cystic fluid (Seewald et al., 2009), ranged from 92% to 100%. However, up to 23 % of pseudocyst recurred during a median follow-up period of 22 months (Binmoeller et al., 1995), giving a long term success rate of 65% to 81% (Aghdassi et al., 2008). In case of fail endoscopic treatment, unfavourable cyst location, such as far from the gastrointestinal lumen, or if neoplasm cannot be excluded, surgery is still the standard procedure of choice (Baillie 2004). Surgical drainage procedures can be in form of cysto-gastrostostomy or cysto-jejunostomy depending on site of the cyst. For pseudocyst masquerading cystic neoplasm, distal pancreatectomy or pancreatoduodenectomy should be advised (Cheung et al., 2008).

### 3.6 Endoscopic ultrasound-guided celiac plexus block

Celiac plexus is located at T12 to L1 level near the take off of celiac trunk adjacent to the aorta. It is a network of ganglia and nerves that lie on both side of the aorta. It contains sympathetic and parasympathetic fibres transmitting signals to and from visceral organ including pancreas. Nociceptive fibres transmitting pain also travel through the celiac plexus. Endoscopic ultrasound allows direct visualization of the celiac plexus region and can even localise the celiac ganglion (Castillo-Roth & Gress, 2010). This enables celiac plexus block to be performed successfully and safely as a non-pharmacological means for pain relief (Avula & Sherman, 2010).

A linear endoendoscope is used to localise the celiac plexus. It’s usually found by passing the endoscope to the posterior lesser curve of gastric fundus and tracing down the aorta to locate the celiac artery take-off at about 40 to 50cm from incisors. Doppler mode can be utilised during the block to ensure the absence of vessels in the path of needle insertion.
A 22-gauge or 19-gauge EUS fine needle aspiration needle is passed through the biopsy channel towards the celiac axis until the tips is inserted to the level of the celiac trunk. After removing the stylet of the needle, a 10ml syringe is attached to the needle system. Aspiration is then applied to ensure the needle is not inside a blood vessel. Bupivicaine and then triamcinolone are then injected in the celiac space after safe needle position is confirmed (Avula & Sherman, 2010). The agent for celiac plexus block can be injected either bilaterally on both sides of the celiac artery origin or just anterior to the take-off of celiac artery and allow the solution to spread to both sides of the vessels (Castillo-Roth & Gress, 2010). It was shown in randomised controlled trial that there was no difference in the technical success, symptom relief and complication rate between bilateral or single site injections (Leblanc et al., 2009). With the advance in endosonographic imaging, localisation of the celiac ganglia and direct ganglia block is possible. While initial data suggested that this approach was safe and effective in initial pain control (Levy et al., 2008), more studies were awaited to evaluate its long-term efficacy and the optimal drugs to be delivered as compared to conventional percutaneous celiac plexus block.

Concerning the overall efficacy in pain control by EUS-guided celiac plexus block, a metaanalysis showed that approximately 60% of patients reported pain relief after the procedure (Pauli et al., 2009). The exact intensity of pain relief and duration of pain control, however, were not described in the metaanalysis. In a series of 90 patients (Gress et al., 2001) receiving EUS-guided celiac plexus block, only 10% of patients had sustained pain reduction at 6 months. This result suggested that further studies on optimal drugs and treatment regimen would be necessary to improve the success rate. In case of refractory pain despite reinterventions, referral to surgery should be considered.

4. Efficacy of endoscopic treatment

Owing to the variety of endoscopic therapy available and the heterogenous nature of the underlying chronic pancreatitis, outcome of endoscopic treatment has to be considered judiciously. In a retrospective review of 125 patients with 324 intraductal stones (Farnbacher et al., 2002), the technical success rate, as defined by stone fragmentations, was reported to be 85%. However, many of these patients required repeated endoscopic intervention plus ESWL. The complete duct clearance rate was only 51%, whereas, 34% patient had partial clearance. For clinical success rate, defined as pain free after treatment, 52% of patients developed relapses of pain and were hospitalized again for treatment. The causes of recurrent pain were mostly due to recurrent stones or malfunction of the pancreatic stents inserted. Thirteen percent of patients in the series required subsequent surgery due to intractable pain after unsuccessful endoscopic treatment.

There were two randomised controlled trials comparing endoscopic treatment to surgical treatment in patients with chronic pancreatitis and pancreatic ductal stones (Dite et al., 2003; Cahen et al., 2007). Both studies concluded that surgery was superior to endoscopic treatment in achieving long term pain control, but they still recommended the use of endoscopic treatment in some selected cases of chronic pancreatitis with less severe ductal obstruction. The techniques employed in the endoscopic treatment arm in these 2 studies had been criticised. The endoscopic arm in study by Dite et al. did not received ESWL,
whereas the endoscopic arm in study by Cahen et al. used stents without side-holes. The latter study was also criticised by the small sample size of total 39 patients (Deviere et al., 2008). Because of the limitation in the randomised controlled studies, endoscopic treatment still played an important role in the management chronic pancreatitis, especially in patients unfit for surgery or refusing surgery (Frulloni et al., 2010). Endoscopic treatment can be proposed as first-line treatment for the following reasons (Khanna & Tandon, 2008) – firstly, it is less invasive than surgery; secondly, it can be repeated in case of relapse of pain; and thirdly, surgery can still be performed in refractory disease as a salvage manoeuvre.

5. Conclusion

Endoscopic therapy can be employed to alleviate pain in patient with chronic pancreatitis. Different endoscopic techniques, including sphincterotomy, stenting, stricture dilatation, stone removal and the insertion of nasopancreatic drain combined with extracorporeal shock wave lithotripsy had been described with successful results. The use of endoscopic ultrasound-guided drainage of pseudocyst and celiac plexus block were also important alternative to surgical treatment. With the advance of endoscopic equipment, improvement of techniques and a better understanding of the pathophysiology of chronic pancreatitis, endoscopic treatment might provide patients a less invasive and comparably effective choice of therapy. However, not all patients were rendered sustained symptomatic relief. Patients with persistent pain or pancreatic mass suspicious of malignancy should be referred for consideration of surgical treatment.

6. References


www.intechopen.com


www.intechopen.com
Chronic Pancreatitis is a disease of diverse etiologies in which pain can be devastating, severely impairing quality of life, and treatment is a challenge. This book covers cutting edge basic science research and clinical diagnosis and treatment issues in chronic pancreatitis. Basic science chapters include studies on amelioration of chronic pancreatitis in rats by bone marrow derived mesenchymal cells; on gene therapy using HSV-Enkephalin to reduce fibrosis, inflammation and pain in a rats; and on pancreatic acinar and island neogenesis according to vascular and matrix dynamics of human and animal tissue. In regard to the clinical aspects, the role of endoscopic ultrasound in detecting the changes of chronic pancreatitis are addressed as well as the endoscopic treatment via duct drainage procedures or stone removal. Finally, the surgical options for chronic pancreatitis (there are well over 20 procedures) are extensively discussed, with a final chapter on total pancreatectomy and islet autotransplant to definitively remove the root cause of the pain with preservation of endocrine function. This book will be valued by basic scientists and clinicians striving to understand the mechanisms of pain in chronic pancreatitis and the treatment options in patients so afflicted.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
